BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 24232581)

  • 1. Metronomic capecitabine in advanced hepatocellular carcinoma patients: a phase II study.
    Brandi G; de Rosa F; Agostini V; di Girolamo S; Andreone P; Bolondi L; Serra C; Sama C; Golfieri R; Gramenzi A; Cucchetti A; Pinna AD; Trevisani F; Biasco G;
    Oncologist; 2013; 18(12):1256-7. PubMed ID: 24232581
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sorafenib versus capecitabine in the management of advanced hepatocellular carcinoma.
    Abdel-Rahman O; Abdel-Wahab M; Shaker M; Abdel-Wahab S; Elbassiony M; Ellithy M
    Med Oncol; 2013; 30(3):655. PubMed ID: 23824645
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-lasting response with metronomic capecitabine in advanced hepatocellular carcinoma.
    Ballardini P; Marri I; Margutti G; Aliberti C; Benea G; Manfredini R
    Tumori; 2010; 96(5):768-70. PubMed ID: 21302626
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metronomic capecitabine as second-line treatment in hepatocellular carcinoma after sorafenib failure.
    Granito A; Marinelli S; Terzi E; Piscaglia F; Renzulli M; Venerandi L; Benevento F; Bolondi L
    Dig Liver Dis; 2015 Jun; 47(6):518-22. PubMed ID: 25861840
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Durable complete response of hepatocellular carcinoma after metronomic capecitabine.
    Brandi G; de Rosa F; Bolondi L; Agostini V; Di Girolamo S; Nobili E; Biasco G
    Tumori; 2010; 96(6):1028-30. PubMed ID: 21388070
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systemic cytotoxic chemotherapy of patients with advanced hepatocellular carcinoma in the era of sorafenib nonavailability.
    Yoon EL; Yeon JE; Lee HJ; Suh SJ; Lee SJ; Kang SH; Kang K; Yoo YJ; Kim JH; Yim HJ; Byun KS
    J Clin Gastroenterol; 2014 Mar; 48(3):e22-9. PubMed ID: 24045282
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase I/II trial of capecitabine combined with peginterferon α-2a in Patients with sorafenib-refractory advanced hepatocellular carcinoma.
    Ogasawara S; Chiba T; Ooka Y; Kanogawa N; Motoyama T; Suzuki E; Tawada A; Kanai F; Yokosuka AO
    Invest New Drugs; 2014 Aug; 32(4):762-8. PubMed ID: 24737402
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metronomic capecitabine as second-line treatment for hepatocellular carcinoma after sorafenib discontinuation.
    Trevisani F; Brandi G; Garuti F; Barbera MA; Tortora R; Casadei Gardini A; Granito A; Tovoli F; De Lorenzo S; Inghilesi AL; Foschi FG; Bernardi M; Marra F; Sacco R; Di Costanzo GG
    J Cancer Res Clin Oncol; 2018 Feb; 144(2):403-414. PubMed ID: 29249005
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II Trial of Sorafenib in Combination with Capecitabine in Patients with Hepatocellular Carcinoma: INST 08-20.
    Patt Y; Rojas-Hernandez C; Fekrazad HM; Bansal P; Lee FC
    Oncologist; 2017 Oct; 22(10):1158-e116. PubMed ID: 28687627
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activity of a multitargeted chemo-switch regimen (sorafenib, gemcitabine, and metronomic capecitabine) in metastatic renal-cell carcinoma: a phase 2 study (SOGUG-02-06).
    Bellmunt J; Trigo JM; Calvo E; Carles J; Pérez-Gracia JL; Rubió J; Virizuela JA; López R; Lázaro M; Albanell J
    Lancet Oncol; 2010 Apr; 11(4):350-7. PubMed ID: 20163987
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma.
    Hsu CH; Yang TS; Hsu C; Toh HC; Epstein RJ; Hsiao LT; Chen PJ; Lin ZZ; Chao TY; Cheng AL
    Br J Cancer; 2010 Mar; 102(6):981-6. PubMed ID: 20160718
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized Phase II Study of the X-linked Inhibitor of Apoptosis (XIAP) Antisense AEG35156 in Combination With Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC).
    Lee FA; Zee BC; Cheung FY; Kwong P; Chiang CL; Leung KC; Siu SW; Lee C; Lai M; Kwok C; Chong M; Jolivet J; Tung S
    Am J Clin Oncol; 2016 Dec; 39(6):609-613. PubMed ID: 24977690
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sustained complete response of advanced hepatocellular carcinoma with metronomic capecitabine: a report of three cases.
    Brandi G; Venturi M; De Lorenzo S; Garuti F; Frega G; Palloni A; Garajovà I; Abbati F; Saccoccio G; Golfieri R; Pantaleo MA; Barbera MA
    Cancer Commun (Lond); 2018 Jun; 38(1):41. PubMed ID: 29941039
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparative study of sorafenib and metronomic chemotherapy for Barcelona Clinic Liver Cancer-stage C hepatocellular carcinoma with poor liver function.
    Yang H; Woo HY; Lee SK; Han JW; Jang B; Nam HC; Lee HL; Lee SW; Song DS; Song MJ; Oh JS; Chun HJ; Jang JW; Lozada A; Bae SH; Choi JY; Yoon SK
    Clin Mol Hepatol; 2017 Jun; 23(2):128-137. PubMed ID: 28494528
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The power of kindness: curative treatment with metronomic combination in advanced hepatocellular carcinoma.
    Brandi G; Di Federico A; Rizzo A; De Lorenzo S; Vasuri F; Brocchi S; Golfieri R; Morelli MC; Frega G; Palloni A
    Anticancer Drugs; 2022 Jan; 33(1):e781-e783. PubMed ID: 34407053
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Duration of stable disease is associated with overall survival in patients with advanced hepatocellular carcinoma treated with sorafenib.
    Arizumi T; Ueshima K; Chishina H; Kono M; Takita M; Kitai S; Inoue T; Yada N; Hagiwara S; Minami Y; Sakurai T; Nishida N; Kudo M
    Dig Dis; 2014; 32(6):705-10. PubMed ID: 25376287
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Capecitabine for treatment of advanced hepatocellular carcinoma.
    von Delius S; Lersch C; Mayr M; Stock K; Schulte-Frohlinde E; Schmid RM; Eckel F
    Hepatogastroenterology; 2007 Dec; 54(80):2310-4. PubMed ID: 18265654
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II Study of Sorafenib Combined with Concurrent Hepatic Arterial Infusion of Oxaliplatin, 5-Fluorouracil and Leucovorin for Unresectable Hepatocellular Carcinoma with Major Portal Vein Thrombosis.
    He MK; Zou RH; Li QJ; Zhou ZG; Shen JX; Zhang YF; Yu ZS; Xu L; Shi M
    Cardiovasc Intervent Radiol; 2018 May; 41(5):734-743. PubMed ID: 29327075
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase 3 tRial comparing capecitabinE in combination with SorafenIb or pLacebo for treatment of locally advanced or metastatIc HER2-Negative breast CancEr (the RESILIENCE study): study protocol for a randomized controlled trial.
    Baselga J; Costa F; Gomez H; Hudis CA; Rapoport B; Roche H; Schwartzberg LS; Petrenciuc O; Shan M; Gradishar WJ
    Trials; 2013 Jul; 14():228. PubMed ID: 23876062
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of metronomic capecitabine for treatment of recurrent hepatocellular carcinoma after liver transplantation.
    Ravaioli M; Cucchetti A; Pinna AD; De Pace V; Neri F; Barbera MA; Maroni L; Frega G; Palloni A; De Lorenzo S; Ripoli MC; Pantaleo MA; Cescon M; Del Gaudio M; Brandi G
    Sci Rep; 2017 Sep; 7(1):11305. PubMed ID: 28900245
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.